{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:07:23Z","timestamp":1787069243395,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.clml.2018.08.019","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T14:53:43Z","timestamp":1536159223000},"page":"e13-e28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France"],"prefix":"10.1016","volume":"19","author":[{"given":"Nicolas","family":"Despi\u00e9gel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Touboul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Flinois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e8ce","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Suzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Gonzalez-McQuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Bonnetain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 6","key":"10.1016\/j.clml.2018.08.019_bib1","doi-asserted-by":"crossref","first-page":"vi133","DOI":"10.1093\/annonc\/mdt297","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Moreau","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.08.019_bib2","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.019_bib4","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.019_bib5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","article-title":"Current treatment landscape for relapsed and\/or refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.019_bib6","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing symptom distress in cancer patients: the MD Anderson Symptom Inventory","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.08.019_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2018.08.019_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","article-title":"Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry","volume":"89","author":"Mols","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2018.08.019_bib10","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00277-014-2264-0","article-title":"Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry","volume":"94","author":"van der Poel","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2018.08.019_bib11","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.2014.120121","article-title":"Health-related quality of life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide","volume":"100","author":"Delforge","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.08.019_bib12","first-page":"599","article-title":"Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey","volume":"21","author":"Acaster","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2018.08.019_bib13","first-page":"417","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study","volume":"22","author":"Jordan","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2018.08.019_bib14","doi-asserted-by":"crossref","unstructured":"Gado K, Domjan G. Quality of life issues of patients with multiple myeloma. In: Hajek R, ed. Multiple Myeloma\u2014A Quick Reflection on the Fast Progress. IntechOpen. 2013. Available: https:\/\/www.intechopen.com\/books\/multiple-myeloma-a-quick-reflection-on-the-fast-progress\/quality-of-life-issues-of-patients-with-multiple-myeloma, Accessed March 2017.","DOI":"10.5772\/55625"},{"key":"10.1016\/j.clml.2018.08.019_bib15","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/leu.2013.185","article-title":"Review of health-related quality of life data in multiple myeloma patients treated with novel agents","volume":"27","author":"Sonneveld","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.08.019_bib16","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2016.66.9648","article-title":"Health-related quality of life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma","volume":"34","author":"Stewart","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.019_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2018.08.019_bib18","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2018.08.019_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12882","article-title":"A\u00a0systematic review of health-related quality of life in longitudinal studies of myeloma patients","volume":"99","author":"Nielsen","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2018.08.019_bib20","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3324\/haematol.2015.127860","article-title":"Health-related quality of life in patients with multiple myeloma\u2014does it matter?","volume":"100","author":"Kvam","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.08.019_bib21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","article-title":"The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2018.08.019_bib22","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V122.21.1721.1721","article-title":"Psychometric performance of the EORTC Quality-of-Life Core Questionnaire (QLQ-C30) and QLQ\u2013Multiple Myeloma (QLQ-MY20) in relapsed\/refractory multiple myeloma (RRMM)","volume":"121","author":"Leleu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.08.019_bib23","author":"World Health Organization"},{"key":"10.1016\/j.clml.2018.08.019_bib24","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.08.019_bib25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/bjh.14193","article-title":"Multiple myeloma: practice patterns across Europe","volume":"175","author":"Raab","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.08.019_bib26","unstructured":"Hu HX, Katic BJ, Lowe M, Purnomo L, Gibson C, Rodrigues AM. Health-related quality of life in patients with multiple myeloma in relation to line of treatment and response. Poster E1459 presented at the 21st Annual European Hematology Association Congress, Copenhagen, Denmark,\u00a02016."},{"issue":"suppl 1","key":"10.1016\/j.clml.2018.08.019_bib27","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0145-2126(12)70007-3","article-title":"How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events","volume":"36","author":"Mateos","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.08.019_bib28","first-page":"3645","article-title":"The level of association between functional performance status measures and patient-reported outcomes in cancer patients: a systematic review","volume":"23","author":"Atkinson","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2018.08.019_bib29","first-page":"6186543","article-title":"Moving beyond Karnofsky and ECOG performance status assessments with new technologies","volume":"2016","author":"Kelly","year":"2016","journal-title":"J\u00a0Oncol"},{"issue":"suppl 4","key":"10.1016\/j.clml.2018.08.019_bib30","doi-asserted-by":"crossref","first-page":"iv123","DOI":"10.1093\/annonc\/mdi921","article-title":"Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials","volume":"16","author":"Gebbia","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2018.08.019_bib31","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/00000421-198812000-00007","article-title":"A\u00a0pilot study of the Functional Living Index\u2013Cancer (FLIC) scale for the assessment of quality of life for metastatic lung cancer patients. An Eastern Cooperative Oncology Group study","volume":"11","author":"Finkelstein","year":"1988","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clml.2018.08.019_bib32","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.bbmt.2018.03.027","article-title":"Health-related quality of life after autologous stem cell transplantation for multiple myeloma","volume":"24","author":"Chakraborty","year":"2018","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018304282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018304282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:18Z","timestamp":1761870738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018304282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S2152265018304282"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.08.019","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-Related Quality of Life of Patients With Multiple Myeloma Treated in Routine Clinical Practice in France","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}